West Pharmaceutical Services (WST) Expected to Release Quarterly Earnings on Thursday

Key Points

• West Pharmaceutical Services is expected to report Q3 2026 results before market open on October 29, with analysts projecting $2.20 in EPS and $827.12 million in revenue.
• The company exceeded expectations in its previous quarter, reporting $2.37 EPS and $872.3 million in revenue, up 13.8% year over year.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and a $391.17 average price target, while the company raised its quarterly dividend to $0.26 per share.

West Pharmaceutical Services (NYSE:WST - Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect West Pharmaceutical Services to announce earnings of $2.20 per share and revenue of $827.12 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period last year, the firm earned $1.84 earnings per share. West Pharmaceutical Services's revenue for the quarter was up 13.8% compared to the same quarter last year. On average, analysts expect West Pharmaceutical Services to post $8.93 EPS for the current fiscal year and $9.90 EPS for the next fiscal year.

West Pharmaceutical Services Price Performance

Shares of West Pharmaceutical Services stock opened at $393.91 on Thursday. West Pharmaceutical Services has a twelve month low of $223.83 and a twelve month high of $396.00. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The company has a 50-day simple moving average of $360.21 and a two-hundred day simple moving average of $335.82. The stock has a market capitalization of $27.72 billion, a price-to-earnings ratio of 50.44, a price-to-earnings-growth ratio of 2.72 and a beta of 1.13.

West Pharmaceutical Services Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th will be given a dividend of $0.26 per share. This is an increase from West Pharmaceutical Services's previous quarterly dividend of $0.22. This represents a $1.04 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, November 10th. West Pharmaceutical Services's dividend payout ratio (DPR) is currently 11.27%.

Analyst Upgrades and Downgrades

A number of research firms have commented on WST. Citigroup raised their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. UBS Group lifted their price objective on West Pharmaceutical Services from $340.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. TD Cowen upped their target price on West Pharmaceutical Services from $410.00 to $420.00 and gave the company a "buy" rating in a research report on Tuesday, October 13th. Evercore reiterated an "outperform" rating and set a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Finally, Zacks Research lowered West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 12th. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $391.17.

Insiders Place Their Bets

In related news, VP Annette Favorite sold 2,524 shares of the firm's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total value of $921,260.00. Following the sale, the vice president directly owned 21,818 shares of the company's stock, valued at $7,963,570. This trade represents a 10.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 15,659 shares of company stock valued at $5,443,749 over the last quarter. Company insiders own 0.60% of the company's stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.